Clinical Report: FDA Approval of Semaglutide 7.2 mg (Wegovy HD) for Obesity
Overview
The FDA has approved semaglutide 7.2 mg (Wegovy HD) for adults with obesity, based on robust weight loss results from the phase 3 STEP UP trials. This once-weekly injectable demonstrated significant mean weight reductions and favorable safety consistent with prior semaglutide studies.
Background
Obesity is a major public health challenge associated with increased risk of type 2 diabetes, cardiovascular disease, and metabolic dysfunction. Semaglutide, a glucagon-like peptide-1 receptor agonist, has been previously approved in lower doses for weight management and related indications. The new 7.2 mg dose (Wegovy HD) aims to provide enhanced efficacy in reducing excess body weight and maintaining long-term weight loss. The FDA’s approval was expedited with a Commissioner’s National Priority Voucher, highlighting its importance in addressing obesity.
Data Highlights
Trial
Population
Duration
Mean Weight Loss (%)
% Achieving ≥20-25% Weight Loss
STEP UP
Adults with obesity (n~1400)
72 weeks
20.7%
31.2% ≥25%
STEP UP T2D
Adults with obesity and type 2 diabetes (n~500)
72 weeks
14.1%
21.3% ≥20%
Key Findings
Semaglutide 7.2 mg once weekly led to a mean weight loss of 20.7% in adults with obesity over 72 weeks.
In adults with obesity and type 2 diabetes, mean weight loss was 14.1% with semaglutide 7.2 mg.
Nearly one-third (31.2%) of patients without diabetes achieved ≥25% weight loss; over one-fifth (21.3%) of patients with diabetes achieved ≥20% weight loss.
The safety and tolerability profile was consistent with previous semaglutide weight management studies.
Wegovy is available in multiple formulations and doses, including injectable (1.7 mg, 2.4 mg, 7.2 mg) and oral forms.
FDA approval includes indications for cardiovascular risk reduction and treatment of metabolic dysfunction–associated steatohepatitis.
Clinical Implications
Semaglutide 7.2 mg offers a potent pharmacologic option for significant and sustained weight loss in adults with obesity, including those with type 2 diabetes. Its favorable safety profile supports its use alongside lifestyle interventions. Clinicians should consider this therapy as part of a comprehensive obesity management plan, especially for patients at high cardiometabolic risk.
Conclusion
The FDA approval of semaglutide 7.2 mg (Wegovy HD) marks an important advancement in obesity treatment, providing a highly effective once-weekly injectable option to achieve substantial weight loss and improve related health outcomes.
References
Novo Nordisk 2024 -- FDA Approves Semaglutide 7.2 mg (Wegovy HD) for Obesity
